Orthofix Medical, Inc. (OFIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.29-0.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Orthofix aims for $838M to $848M revenue in 2026. The company targets positive free cash flow this year. Recent earnings beats show improving execution. The stock trades cheaply versus peers.
Reimbursement cuts threaten revenue growth. The company is still loss-making with negative free cash flow. Leadership changes and guidance cuts add uncertainty.
The market expects about 4.5% revenue growth and values Orthofix well below our fair value of $36.52. Our view is more optimistic on recovery and cash flow improvement.
Breaks if: free cash flow remains negative through FY26
Breaks if: significant executive departures or governance issues arise
Breaks if: annual revenue falls below $810M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story. OFIX is currently loss-making but is focused on achieving revenue growth and improving margins over the next few years. The thesis remains intact despite recent mixed financial results.
The market appears to have priced in a low level of fragility, with the valuation seen as cheap compared to peers. Expectations are slightly negative, indicating that the market may be cautious about OFIX's ability to deliver on its financial targets.
Management is on track to meet revenue and EBITDA targets, but progress toward positive free cash flow has been mixed. Recent earnings beats suggest some operational strength, but the overall financial performance has been neutral.
The long-term thesis hinges on management's ability to maintain guidance and deliver on financial targets. Additionally, broader sector performance and economic conditions, such as job growth, will play a significant role in shaping OFIX's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on OFIX. However, analysts trimmed the Q2 outlook, which threatens revenue growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, OFIX's performance will depend on its execution against stated goals and external economic factors. Not investment advice.